| pubmed-article:9733598 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9733598 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:9733598 | lifeskim:mentions | umls-concept:C0302600 | lld:lifeskim |
| pubmed-article:9733598 | lifeskim:mentions | umls-concept:C0032140 | lld:lifeskim |
| pubmed-article:9733598 | lifeskim:mentions | umls-concept:C0091573 | lld:lifeskim |
| pubmed-article:9733598 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9733598 | pubmed:dateCreated | 1998-9-24 | lld:pubmed |
| pubmed-article:9733598 | pubmed:abstractText | The activation of the zymogen plasminogen to the serine protease plasmin by urokinase-type (uPA) and tissue-type (tPA) plasminogen activators (PA) is an important event in a variety of physiologic and pathophysiologic processes in mammals. Enhanced PA activity occurs during angiogenesis and has been correlated in vitro and in vivo with increased tumor aggressiveness and is an indicator of poor prognosis in a variety of tumors in humans. Preliminary studies suggest that the antiulcer drug irsogladine maleate (IM) diminishes PA activity in vitro and may inhibit angiogenesis in vivo. To define the precise mechanism of angiogenesis inhibition by IM in vivo, we tested the ability of IM to blunt angiogenesis in a mouse cornea neovascularization model performed in wild-type and PA-knockout mice. | lld:pubmed |
| pubmed-article:9733598 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9733598 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9733598 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9733598 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9733598 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9733598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9733598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9733598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9733598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9733598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9733598 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9733598 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:9733598 | pubmed:issn | 0022-4804 | lld:pubmed |
| pubmed-article:9733598 | pubmed:author | pubmed-author:RifkinD BDB | lld:pubmed |
| pubmed-article:9733598 | pubmed:author | pubmed-author:MignattiPP | lld:pubmed |
| pubmed-article:9733598 | pubmed:author | pubmed-author:UedaFF | lld:pubmed |
| pubmed-article:9733598 | pubmed:author | pubmed-author:RosesD FDF | lld:pubmed |
| pubmed-article:9733598 | pubmed:author | pubmed-author:HarrisM NMN | lld:pubmed |
| pubmed-article:9733598 | pubmed:author | pubmed-author:ShapiroR LRL | lld:pubmed |
| pubmed-article:9733598 | pubmed:author | pubmed-author:RenC JCJ | lld:pubmed |
| pubmed-article:9733598 | pubmed:copyrightInfo | Copyright 1998 Academic Press. | lld:pubmed |
| pubmed-article:9733598 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9733598 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9733598 | pubmed:volume | 77 | lld:pubmed |
| pubmed-article:9733598 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9733598 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9733598 | pubmed:pagination | 126-31 | lld:pubmed |
| pubmed-article:9733598 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9733598 | pubmed:meshHeading | pubmed-meshheading:9733598-... | lld:pubmed |
| pubmed-article:9733598 | pubmed:meshHeading | pubmed-meshheading:9733598-... | lld:pubmed |
| pubmed-article:9733598 | pubmed:meshHeading | pubmed-meshheading:9733598-... | lld:pubmed |
| pubmed-article:9733598 | pubmed:meshHeading | pubmed-meshheading:9733598-... | lld:pubmed |
| pubmed-article:9733598 | pubmed:meshHeading | pubmed-meshheading:9733598-... | lld:pubmed |
| pubmed-article:9733598 | pubmed:meshHeading | pubmed-meshheading:9733598-... | lld:pubmed |
| pubmed-article:9733598 | pubmed:meshHeading | pubmed-meshheading:9733598-... | lld:pubmed |
| pubmed-article:9733598 | pubmed:meshHeading | pubmed-meshheading:9733598-... | lld:pubmed |
| pubmed-article:9733598 | pubmed:meshHeading | pubmed-meshheading:9733598-... | lld:pubmed |
| pubmed-article:9733598 | pubmed:meshHeading | pubmed-meshheading:9733598-... | lld:pubmed |
| pubmed-article:9733598 | pubmed:meshHeading | pubmed-meshheading:9733598-... | lld:pubmed |
| pubmed-article:9733598 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9733598 | pubmed:articleTitle | Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. | lld:pubmed |
| pubmed-article:9733598 | pubmed:affiliation | Department of Surgery, New York University School of Medicine, New York, New York, 10016, USA. | lld:pubmed |
| pubmed-article:9733598 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9733598 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9733598 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
